Skip to main content
Erschienen in: International Urology and Nephrology 11/2021

24.04.2021 | Nephrology - Original Paper

Hyperuricemia and hypertriglyceridemia indicate tubular atrophy/interstitial fibrosis in patients with IgA nephropathy and membranous nephropathy

verfasst von: Bingman Liu, Liangyu Zhao, Qingqing Yang, Dongqing Zha, Xiaoyun Si

Erschienen in: International Urology and Nephrology | Ausgabe 11/2021

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Hyperuricemia (HUA) and hypertriglyceridemia (HTG) were very common in chronic kidney disease (CKD) and associated with accelerated progression of CKD. This was a retrospective, cross-sectional study which aimed to explore the relationship between serum uric acid levels or triglyceride levels and tubular atrophy/interstitial fibrosis (proven by renal biopsy).

Methods

The present study enrolled 229 CKD individuals who included 127 biopsy-proven primary IgA nephrology (IgAN) patients and 102 biopsy-proven primary membranous nephropathy (MN) patients. The baseline characteristics at the time of the kidney biopsy were collected. According to the serum uric acid (UA) or triglyceride (TG) whether it exceeds the normal reference range, patients were divided into non-HUA (n = 127), HUA (n = 102), non-HTG (n = 119), and HTG group (n = 110). Based on the extent of tubular atrophy/interstitial fibrosis, patients were divided into no/mild injury (T0, n = 127), moderate injury (T1, n = 102). Multivariable logistic regression for factors predicting moderate tubular atrophy/interstitial fibrosis was performed.

Results

There were 127 IgAN and 102 MN cases among 229 patients in the present study. The prevalence of HUA was 44.5% (n = 102), 40.9% (n = 52), and 49.0% (n = 50) in all patients, IgAN patients and MN patients, respectively (P = 1.49). The prevalence of HTG was 48.0% (n = 110), 29.9% (n = 38), and 70.6% (n = 72) (P < 0.001), respectively, as well. Multivariate logistic regression analysis showed that HUA and HTG were independent risk factors for moderate tubular atrophy/interstitial fibrosis (HUA OR = 2.335, 95% CI = 1.147–4.755, P = 0.019; HTG OR = 2.646, 95% CI = 1.289–5.432, P = 0.008). The area under curve (AUC) of model 1 (HUA + eGFR + HTG + age + serum globulin + 24 h urinary protein, AUC = 0.876) was larger than the other two models; however, there was no significant difference among these models (all P > 0.05).

Conclusions

Hyperuricemia and hypertriglyceridemia, which were prevalent in CKD patients, were the independent risk factors for moderate tubular atrophy/interstitial fibrosis. HUA together with HTG could improve the value of diagnosis for moderate tubular atrophy/interstitial fibrosis to some extent.
Literatur
1.
Zurück zum Zitat Li L, Yang C, Zhao Y et al (2014) Is hyperuricemia an independent risk factor for new-onset chronic kidney disease? A systematic review and meta-analysis based on observational cohort studies. BMC Nephrol 15:122PubMedPubMedCentralCrossRef Li L, Yang C, Zhao Y et al (2014) Is hyperuricemia an independent risk factor for new-onset chronic kidney disease? A systematic review and meta-analysis based on observational cohort studies. BMC Nephrol 15:122PubMedPubMedCentralCrossRef
2.
Zurück zum Zitat Tsuruya K, Yoshida H, Nagata M et al (2017) Association of hypertriglyceridemia with the incidence and progression of chronic kidney disease and modification of the association by daily alcohol consumption. J Ren Nutr 27(6):381–394PubMedCrossRef Tsuruya K, Yoshida H, Nagata M et al (2017) Association of hypertriglyceridemia with the incidence and progression of chronic kidney disease and modification of the association by daily alcohol consumption. J Ren Nutr 27(6):381–394PubMedCrossRef
3.
Zurück zum Zitat Tsuruya K, Yoshida H, Nagata M et al (2015) Impact of the triglycerides to high-density lipoprotein cholesterol ratio on the incidence and progression of ckd: a longitudinal study in a large Japanese population. Am J Kidney Dis 66(6):972–983PubMedCrossRef Tsuruya K, Yoshida H, Nagata M et al (2015) Impact of the triglycerides to high-density lipoprotein cholesterol ratio on the incidence and progression of ckd: a longitudinal study in a large Japanese population. Am J Kidney Dis 66(6):972–983PubMedCrossRef
4.
Zurück zum Zitat Xue N, Fang Y, Ding X et al (2019) Serum triglycerides are related to chronic kidney disease (CKD) stage 2 in young and middle-aged chinese individuals during routine health examination. Med Sci Monit 25:2445–2451PubMedPubMedCentralCrossRef Xue N, Fang Y, Ding X et al (2019) Serum triglycerides are related to chronic kidney disease (CKD) stage 2 in young and middle-aged chinese individuals during routine health examination. Med Sci Monit 25:2445–2451PubMedPubMedCentralCrossRef
5.
Zurück zum Zitat Toth PP, Philip S, Hull M et al (2019) Elevated triglycerides (≥150 mg/dL) and high triglycerides (200–499 mg/dl) are significant predictors of hospitalization for new-onset kidney disease: a real-world analysis of high-risk statin-treated patients. CardioRenal Med 9(6):400–407PubMedCrossRef Toth PP, Philip S, Hull M et al (2019) Elevated triglycerides (≥150 mg/dL) and high triglycerides (200–499 mg/dl) are significant predictors of hospitalization for new-onset kidney disease: a real-world analysis of high-risk statin-treated patients. CardioRenal Med 9(6):400–407PubMedCrossRef
6.
Zurück zum Zitat Tsai CW, Lin SY, Kuo CC et al (2017) Serum uric acid and progression of kidney disease: a longitudinal analysis and mini-review. PLoS ONE 12(1):e170393 Tsai CW, Lin SY, Kuo CC et al (2017) Serum uric acid and progression of kidney disease: a longitudinal analysis and mini-review. PLoS ONE 12(1):e170393
7.
Zurück zum Zitat Hsieh YP, Chang CC, Yang Y et al (2017) The role of uric acid in chronic kidney disease patients. Nephrology 22(6):441–448PubMedCrossRef Hsieh YP, Chang CC, Yang Y et al (2017) The role of uric acid in chronic kidney disease patients. Nephrology 22(6):441–448PubMedCrossRef
8.
Zurück zum Zitat Weaver DJ (2019) Uric acid and progression of chronic kidney disease. Pediatr Nephrol 34(5):801–809PubMedCrossRef Weaver DJ (2019) Uric acid and progression of chronic kidney disease. Pediatr Nephrol 34(5):801–809PubMedCrossRef
9.
Zurück zum Zitat Caliskan Y, Ozluk Y, Celik D et al (2016) The clinical significance of uric acid and complement activation in the progression of IgA nephropathy. Kidney Blood Press Res 41(2):148–157PubMedCrossRef Caliskan Y, Ozluk Y, Celik D et al (2016) The clinical significance of uric acid and complement activation in the progression of IgA nephropathy. Kidney Blood Press Res 41(2):148–157PubMedCrossRef
10.
Zurück zum Zitat Zhu B, Yu DR, Lv JC et al (2018) Uric acid as a predictor of immunoglobulin a nephropathy progression: a cohort study of 1965 cases. Am J Nephrol 48(2):127–136PubMedCrossRef Zhu B, Yu DR, Lv JC et al (2018) Uric acid as a predictor of immunoglobulin a nephropathy progression: a cohort study of 1965 cases. Am J Nephrol 48(2):127–136PubMedCrossRef
11.
Zurück zum Zitat Syrjanen J, Mustonen J, Pasternack A (2000) Hypertriglyceridaemia and hyperuricaemia are risk factors for progression of IgA nephropathy. Nephrol Dial Transplant 15(1):34–42PubMedCrossRef Syrjanen J, Mustonen J, Pasternack A (2000) Hypertriglyceridaemia and hyperuricaemia are risk factors for progression of IgA nephropathy. Nephrol Dial Transplant 15(1):34–42PubMedCrossRef
12.
Zurück zum Zitat Wang J, He L, Yan W et al (2020) The role of hypertriglyceridemia and treatment patterns in the progression of IgA nephropathy with a high proportion of global glomerulosclerosis. Int Urol Nephrol 52(2):325–335PubMedCrossRef Wang J, He L, Yan W et al (2020) The role of hypertriglyceridemia and treatment patterns in the progression of IgA nephropathy with a high proportion of global glomerulosclerosis. Int Urol Nephrol 52(2):325–335PubMedCrossRef
13.
Zurück zum Zitat Moorhead JF, Chan MK, El-Nahas M et al (1982) Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease. Lancet 2(8311):1309–1311PubMedCrossRef Moorhead JF, Chan MK, El-Nahas M et al (1982) Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease. Lancet 2(8311):1309–1311PubMedCrossRef
14.
Zurück zum Zitat Srivastava A, Kaze AD, McMullan CJ et al (2018) Uric acid and the risks of kidney failure and death in individuals with CKD. Am J Kidney Dis 71(3):362–370PubMedCrossRef Srivastava A, Kaze AD, McMullan CJ et al (2018) Uric acid and the risks of kidney failure and death in individuals with CKD. Am J Kidney Dis 71(3):362–370PubMedCrossRef
16.
Zurück zum Zitat Waring WS, Webb DJ, Maxwell SR (2001) Systemic uric acid administration increases serum antioxidant capacity in healthy volunteers. J Cardiovasc Pharmacol 38(3):365–371PubMedCrossRef Waring WS, Webb DJ, Maxwell SR (2001) Systemic uric acid administration increases serum antioxidant capacity in healthy volunteers. J Cardiovasc Pharmacol 38(3):365–371PubMedCrossRef
17.
18.
Zurück zum Zitat Peng TC, Wang CC, Kao TW et al (2015) Relationship between hyperuricemia and lipid profiles in US adults. Biomed Res Int 2015:127596PubMedPubMedCentral Peng TC, Wang CC, Kao TW et al (2015) Relationship between hyperuricemia and lipid profiles in US adults. Biomed Res Int 2015:127596PubMedPubMedCentral
19.
Zurück zum Zitat Zheng R, Ren P, Chen Q et al (2017) Serum uric acid levels and risk of incident hypertriglyceridemia: a longitudinal population-based epidemiological study. Ann Clin Lab Sci 47(5):586–591PubMed Zheng R, Ren P, Chen Q et al (2017) Serum uric acid levels and risk of incident hypertriglyceridemia: a longitudinal population-based epidemiological study. Ann Clin Lab Sci 47(5):586–591PubMed
20.
Zurück zum Zitat Kuwabara M, Borghi C, Cicero A et al (2018) Elevated serum uric acid increases risks for developing high LDL cholesterol and hypertriglyceridemia: a five-year cohort study in Japan. Int J Cardiol 261:183–188PubMedCrossRef Kuwabara M, Borghi C, Cicero A et al (2018) Elevated serum uric acid increases risks for developing high LDL cholesterol and hypertriglyceridemia: a five-year cohort study in Japan. Int J Cardiol 261:183–188PubMedCrossRef
21.
Zurück zum Zitat Roberts IS, Cook HT, Troyanov S et al (2009) The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility. Kidney Int 76(5):546–556PubMedCrossRef Roberts IS, Cook HT, Troyanov S et al (2009) The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility. Kidney Int 76(5):546–556PubMedCrossRef
22.
Zurück zum Zitat Cattran DC, Coppo R, Cook HT et al (2009) The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int 76(5):534–545PubMedCrossRef Cattran DC, Coppo R, Cook HT et al (2009) The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int 76(5):534–545PubMedCrossRef
23.
Zurück zum Zitat National Kidney Foundation (2002) K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 39(2 Suppl 1):S1–S266 National Kidney Foundation (2002) K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 39(2 Suppl 1):S1–S266
25.
Zurück zum Zitat Ruan Y, Hong F, Wu J et al (2018) Clinicopathological characteristics, role of immunosuppressive therapy and progression in IgA nephropathy with hyperuricemia. Kidney Blood Press Res 43(4):1131–1140PubMedCrossRef Ruan Y, Hong F, Wu J et al (2018) Clinicopathological characteristics, role of immunosuppressive therapy and progression in IgA nephropathy with hyperuricemia. Kidney Blood Press Res 43(4):1131–1140PubMedCrossRef
27.
Zurück zum Zitat Zhou J, Chen Y, Liu Y et al (2014) Plasma uric acid level indicates tubular interstitial leisions at early stage of IgA nephropathy. BMC Nephrol 15:11PubMedPubMedCentralCrossRef Zhou J, Chen Y, Liu Y et al (2014) Plasma uric acid level indicates tubular interstitial leisions at early stage of IgA nephropathy. BMC Nephrol 15:11PubMedPubMedCentralCrossRef
28.
Zurück zum Zitat Myllymaki J, Honkanen T, Syrjanen J et al (2005) Uric acid correlates with the severity of histopathological parameters in IgA nephropathy. Nephrol Dial Transplant 20(1):89–95PubMedCrossRef Myllymaki J, Honkanen T, Syrjanen J et al (2005) Uric acid correlates with the severity of histopathological parameters in IgA nephropathy. Nephrol Dial Transplant 20(1):89–95PubMedCrossRef
29.
Zurück zum Zitat Ames BN, Cathcart R, Schwiers E et al (1981) Uric acid provides an antioxidant defense in humans against oxidant and radical-caused aging and cancer: a hypothesis. Proc Natl Acad Sci USA 78(11):6858–6862PubMedPubMedCentralCrossRef Ames BN, Cathcart R, Schwiers E et al (1981) Uric acid provides an antioxidant defense in humans against oxidant and radical-caused aging and cancer: a hypothesis. Proc Natl Acad Sci USA 78(11):6858–6862PubMedPubMedCentralCrossRef
30.
Zurück zum Zitat Glantzounis GK, Tsimoyiannis EC, Kappas AM et al (2005) Uric acid and oxidative stress. Curr Pharm Des 11(32):4145–4151PubMedCrossRef Glantzounis GK, Tsimoyiannis EC, Kappas AM et al (2005) Uric acid and oxidative stress. Curr Pharm Des 11(32):4145–4151PubMedCrossRef
31.
Zurück zum Zitat Yang D, Su Z, Wu S et al (2016) Low antioxidant status of serum bilirubin, uric acid, albumin and creatinine in patients with myasthenia gravis. Int J Neurosci 126(12):1120–1126PubMedCrossRef Yang D, Su Z, Wu S et al (2016) Low antioxidant status of serum bilirubin, uric acid, albumin and creatinine in patients with myasthenia gravis. Int J Neurosci 126(12):1120–1126PubMedCrossRef
32.
Zurück zum Zitat Ljubisavljevic S, Stojanovic I, Vojinovic S et al (2013) Association of serum bilirubin and uric acid levels changes during neuroinflammation in patients with initial and relapsed demyelination attacks. Metab Brain Dis 28(4):629–638PubMedCrossRef Ljubisavljevic S, Stojanovic I, Vojinovic S et al (2013) Association of serum bilirubin and uric acid levels changes during neuroinflammation in patients with initial and relapsed demyelination attacks. Metab Brain Dis 28(4):629–638PubMedCrossRef
33.
Zurück zum Zitat Zhou Y, Fang L, Jiang L et al (2012) Uric acid induces renal inflammation via activating tubular NF-kappaB signaling pathway. PLoS ONE 7(6):e39738PubMedPubMedCentralCrossRef Zhou Y, Fang L, Jiang L et al (2012) Uric acid induces renal inflammation via activating tubular NF-kappaB signaling pathway. PLoS ONE 7(6):e39738PubMedPubMedCentralCrossRef
34.
Zurück zum Zitat Kurts C (2013) A crystal-clear mechanism of chronic kidney disease. Kidney Int 84(5):859–861PubMedCrossRef Kurts C (2013) A crystal-clear mechanism of chronic kidney disease. Kidney Int 84(5):859–861PubMedCrossRef
35.
Zurück zum Zitat Yu MA, Sanchez-Lozada LG, Johnson RJ et al (2010) Oxidative stress with an activation of the renin-angiotensin system in human vascular endothelial cells as a novel mechanism of uric acid-induced endothelial dysfunction. J Hypertens 28(6):1234–1242PubMedCrossRef Yu MA, Sanchez-Lozada LG, Johnson RJ et al (2010) Oxidative stress with an activation of the renin-angiotensin system in human vascular endothelial cells as a novel mechanism of uric acid-induced endothelial dysfunction. J Hypertens 28(6):1234–1242PubMedCrossRef
36.
Zurück zum Zitat Corry DB, Eslami P, Yamamoto K et al (2008) Uric acid stimulates vascular smooth muscle cell proliferation and oxidative stress via the vascular renin-angiotensin system. J Hypertens 26(2):269–275PubMedCrossRef Corry DB, Eslami P, Yamamoto K et al (2008) Uric acid stimulates vascular smooth muscle cell proliferation and oxidative stress via the vascular renin-angiotensin system. J Hypertens 26(2):269–275PubMedCrossRef
37.
Zurück zum Zitat Zoccali C, Maio R, Mallamaci F et al (2006) Uric acid and endothelial dysfunction in essential hypertension. J Am Soc Nephrol 17(5):1466–1471PubMedCrossRef Zoccali C, Maio R, Mallamaci F et al (2006) Uric acid and endothelial dysfunction in essential hypertension. J Am Soc Nephrol 17(5):1466–1471PubMedCrossRef
38.
Zurück zum Zitat Mallat SG, Al KS, Tanios BY et al (2016) Hyperuricemia, hypertension, and chronic kidney disease: an emerging association. Curr Hypertens Rep 18(10):74PubMedCrossRef Mallat SG, Al KS, Tanios BY et al (2016) Hyperuricemia, hypertension, and chronic kidney disease: an emerging association. Curr Hypertens Rep 18(10):74PubMedCrossRef
39.
Zurück zum Zitat Ryu ES, Kim MJ, Shin HS et al (2013) Uric acid-induced phenotypic transition of renal tubular cells as a novel mechanism of chronic kidney disease. Am J Physiol Renal Physiol 304(5):F471–F480PubMedCrossRef Ryu ES, Kim MJ, Shin HS et al (2013) Uric acid-induced phenotypic transition of renal tubular cells as a novel mechanism of chronic kidney disease. Am J Physiol Renal Physiol 304(5):F471–F480PubMedCrossRef
40.
Zurück zum Zitat Du XG, Ruan XZ (2019) Lipid metabolism disorder and renal fibrosis. Adv Exp Med Biol 1165:525–541PubMedCrossRef Du XG, Ruan XZ (2019) Lipid metabolism disorder and renal fibrosis. Adv Exp Med Biol 1165:525–541PubMedCrossRef
41.
Zurück zum Zitat Sanchez-Lozada LG, Tapia E, Santamaria J et al (2005) Mild hyperuricemia induces vasoconstriction and maintains glomerular hypertension in normal and remnant kidney rats. Kidney Int 67(1):237–247PubMedCrossRef Sanchez-Lozada LG, Tapia E, Santamaria J et al (2005) Mild hyperuricemia induces vasoconstriction and maintains glomerular hypertension in normal and remnant kidney rats. Kidney Int 67(1):237–247PubMedCrossRef
42.
Zurück zum Zitat Sanchez-Lozada LG, Tapia E, Soto V et al (2008) Treatment with the xanthine oxidase inhibitor febuxostat lowers uric acid and alleviates systemic and glomerular hypertension in experimental hyperuricaemia. Nephrol Dial Transplant 23(4):1179–1185PubMedCrossRef Sanchez-Lozada LG, Tapia E, Soto V et al (2008) Treatment with the xanthine oxidase inhibitor febuxostat lowers uric acid and alleviates systemic and glomerular hypertension in experimental hyperuricaemia. Nephrol Dial Transplant 23(4):1179–1185PubMedCrossRef
43.
Zurück zum Zitat Goicoechea M, de Vinuesa SG, Verdalles U et al (2010) Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol 5(8):1388–1393PubMedPubMedCentralCrossRef Goicoechea M, de Vinuesa SG, Verdalles U et al (2010) Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol 5(8):1388–1393PubMedPubMedCentralCrossRef
Metadaten
Titel
Hyperuricemia and hypertriglyceridemia indicate tubular atrophy/interstitial fibrosis in patients with IgA nephropathy and membranous nephropathy
verfasst von
Bingman Liu
Liangyu Zhao
Qingqing Yang
Dongqing Zha
Xiaoyun Si
Publikationsdatum
24.04.2021
Verlag
Springer Netherlands
Erschienen in
International Urology and Nephrology / Ausgabe 11/2021
Print ISSN: 0301-1623
Elektronische ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-021-02844-4

Weitere Artikel der Ausgabe 11/2021

International Urology and Nephrology 11/2021 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.